Dang-Tan Tam, Ismaila Afisi, Zhang Shiyuan, Zarotsky Victoria, Bernauer Mark
GlaxoSmithKline, 7333 Mississauga Road, Mississauga, ON, L5N 6L4, Canada.
GlaxoSmithKline, Research Triangle Park, NC, USA.
BMC Res Notes. 2015 Sep 21;8:464. doi: 10.1186/s13104-015-1427-y.
Chronic obstructive pulmonary disease (COPD) is a chronic, irreversible disease and a leading cause of worldwide morbidity and mortality. In Canada, COPD is the fourth leading cause of death. This systematic review was undertaken to update healthcare professionals and decision makers regarding the recent clinical, humanistic and economic burden evidence in Canada.
A systematic literature search was conducted in PubMed, EMBASE, and Cochrane databases to identify original research published January 2000 through December 2012 on the burden of COPD in Canada. Each search was conducted using controlled vocabulary and key words, with "COPD" as the main search concept and limited to Canadian studies, written in English and involving human subjects. Selected studies included randomized controlled trials, observational studies and systematic reviews/meta-analyses that reported healthcare resource utilization, quality of life and/or healthcare costs.
Of the 972 articles identified through the literature searches, 70 studies were included in this review. These studies were determined to have an overall good quality based on the quality assessment. COPD patients were found to average 0-4 annual emergency department visits, 0.3-1.5 annual hospital visits, and 0.7-5 annual physician visits. Self-care management was found to lessen the overall risk of emergency department (ED) visits, hospitalization and unscheduled physician visits. Additionally, integrated care decreased the mean number of hospitalizations and telephone support reduced the number of annual physician visits. Overall, 60-68 % of COPD patients were found to be inactive and 60-72 % reported activity restriction. Pain was found to negatively correlate with physical activity while breathing difficulties resulted in an inability to leave home and reduced the ability to handle activities of daily living. Evidence indicated that treating COPD improved patients' overall quality of life. The average total cost per patient ranged between CAN $2444-4391 from a patient perspective to CAN $3910-6693 from a societal perspective. Furthermore, evidence indicated that COPD exacerbations lead to higher costs.
The clinical, humanistic and economic burden of COPD in Canada is substantial. Use of self-care management programs, telephone support, and integrated care may reduce the overall burden to Canadian patients and society.
慢性阻塞性肺疾病(COPD)是一种慢性、不可逆的疾病,是全球发病和死亡的主要原因。在加拿大,COPD是第四大死因。本系统评价旨在向医疗保健专业人员和决策者更新有关加拿大近期临床、人文和经济负担的证据。
在PubMed、EMBASE和Cochrane数据库中进行系统的文献检索,以识别2000年1月至2012年12月发表的关于加拿大COPD负担的原创研究。每次检索均使用控制词汇和关键词,以“COPD”作为主要检索概念,仅限于加拿大研究,用英语撰写且涉及人类受试者。选定的研究包括随机对照试验、观察性研究以及报告医疗资源利用、生活质量和/或医疗成本的系统评价/荟萃分析。
通过文献检索确定的972篇文章中,本评价纳入了70项研究。根据质量评估,这些研究被确定总体质量良好。发现COPD患者平均每年急诊就诊0 - 4次,每年住院0.3 - 1.5次,每年看医生0.7 - 5次。自我护理管理被发现可降低急诊就诊、住院和非预约看医生的总体风险。此外,综合护理减少了住院的平均次数,电话支持减少了每年看医生的次数。总体而言,发现60 - 68%的COPD患者不活动,60 - 72%的患者报告有活动受限。发现疼痛与身体活动呈负相关,而呼吸困难导致无法离家并降低了处理日常生活活动的能力。证据表明,治疗COPD可改善患者的总体生活质量。从患者角度看,每位患者的平均总成本在2444加元至4391加元之间,从社会角度看在3910加元至6693加元之间。此外,证据表明COPD急性加重会导致更高的成本。
加拿大COPD的临床、人文和经济负担很重。使用自我护理管理计划、电话支持和综合护理可能会减轻加拿大患者和社会的总体负担。